No Stock Yet
GemPharmatech Co., Ltd. (SHSE:688046) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
With its stock down 9.4% over the past month, it is easy to disregard GemPharmatech (SHSE:688046). However, the company's fundamentals look pretty decent, and long-term financials are usually aligne
GemPharmatech Co., Ltd.'s (SHSE:688046) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
With its stock down 21% over the past month, it is easy to disregard GemPharmatech (SHSE:688046). However, stock prices are usually driven by a company's financials over the long term, which in this
GemPharmatech's (SHSE:688046) Robust Earnings Are Not All Good News For Shareholders
Even though GemPharmatech Co., Ltd. (SHSE:688046) posted strong earnings recently, the stock hasn't reacted in a large way. We think that investors might be worried about the foundations the earnings
GemPharmatech and Charles River Laboratories Sign Exclusive Agreement to Distribute Next Generation NCG Portfolio
WILMINGTON, Del., July 26, 2022 /PRNewswire/ -- In order to bring new cutting-edge research models to the market to accelerate the development of novel therapeutics for a host of unmet medical needs
Is GemPharmatech Co., Ltd.'s (SHSE:688046) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
GemPharmatech (SHSE:688046) has had a great run on the share market with its stock up by a significant 90% over the last three months. Since the market usually pay for a company's long-term fundamen
Yakang Biology (688046.SH): Plans to use no more than 500 million yuan of its own idle funds for entrusted financial management
Gelonghui, May 18, 丨 Yaokang Biotech (688046.SH) announced that the company held the 12th meeting of the first board of directors on May 17, 2022 to review the “Proposal on Using Idle Own Funds for Entrusted Financial Management” and agreed that the company would use no more than RMB 500 million (including capital) of its own idle funds for entrusted financial management without affecting normal operations. The validity period is valid from the date the board of directors deliberates and approval until the next year when the board of directors considers the use of idle own funds to entrust financial management matters. Funds can be recycled and used on a rolling basis within the above amount and validity period. The board of directors authorized the general manager or
Yakang Biotech (688046.SH) plans not to distribute profits in 2021
According to the Zhitong Finance App, Yakang Biotech (688046.SH) announced that the company's net profit attributable to shareholders of listed companies in 2021 was 125 million yuan, and the net profit of the parent company was 143 million yuan. In view of the fact that the company is currently in a period of rapid development, the scale of operation continues to expand, and capital requirements are high. In order to smoothly promote the construction of the company's product production capacity, the company plans not to distribute cash dividends in 2021, not to send bonus shares, not to use capital reserve funds to increase share capital, and undistributed profits will be carried over to the next year.
Drug Health Biology (688046.SH): it is proposed to use some of the over-raised funds of 60 million yuan to permanently replenish the working capital.
688046.SH announced that the company held the 12th meeting of the first session of the Board of Directors and the sixth meeting of the first session of the Supervisory Committee on May 17, 2022, examined and passed the "Bill on the use of over-raised funds to permanently replenish current funds" and agreed to use some of the over-raised funds of 60 million yuan to permanently replenish liquidity. The matter needs to be submitted to the shareholders' general meeting of the company for consideration and approval before it can be implemented.
Yao Kang Biology (688046): based on animal model to build products and services to explore the new boundary of the industry
Report on the pricing of New shares of Yao Kang Bio (688046)
No Stock Yet